Article Sidebar
Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
Mid-trimester termination ofpregnancy - a randomised controlled trial of two prostaglandin regitnens
Abstract
Objective. To detennine the more applicable of two ways of prostaglandin induction currently in use in second trimester induced abortions for congenital or chromosomal abnormalities.
Design. A prospective randomised controlled trial.
Setting. Department of Obstetrics and Gynaecology, Tygerberg Hospital, CP.
Study population. Twenty consecutive patients admitted for tennination of pregnancy for congenital or chromosomal abnormalities between 14 and 26 weeks' pregnancy duration. Management. Patients were randomly selected to receive either 1,5 mg prostaglandin E, (PGE,) gel extra-amniotically or 25 mg prostaglandin F,a (PGF,a) intra-amniotically. Patients in both groups received oxytocin to a maximum dosage of 120 IllU per minute if they had not aborted 18 hours after the original administration of either prostaglandin regimen. If abortion had not taken place 36 hours after cotnmencement of treatment, management was considered unsuccessful.
Main outcome measurements. Proportion of successful inductions and complications.
Results. Complications of management were rare and did not differ between the two management groups. However, there were significantly more failures in the group who receh'ed intraamniotic PGF,a (7 v. 2 patients) as well as a significantly higher need for oxytocin in this group (10 v. 4 patients).
Conclusions. With· proIllising drugs such as prostaglandin analogues and anti-progesterones not universally available, methods of induction suitable to the local situation should be sought. Extra-atnniotic PGE, seems more suitable than intra-amniotic PGF,a because of a shorter induction- to-delivery time without increased morbidity.
